← All indications
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
Subtype terms (1)
More specific conditions that are subtypes of Acute Kidney Injury in the MeSH hierarchy.
- Kidney Tubular Necrosis, Acute
8 drugs (6 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (63)
- phenobarbital
- ringer's lactate
- phenylephrine
- sodium citrate
- allopurinol
- propofol
- heparin
- acetylcysteine
- kremezin
- norepinephrine
- ketamine
- cidofovir
- alpha-lipoic acid
- digoxin immune fab (ovine)
- valproic acid
- empagliflozin
- sevoflurane
- famotidine
- albumin (Human)
- ketorolac
- ganciclovir
- levetiracetam
- magnesium oxide
- iopamidol
- levosimendan
- lithium
- nitric oxide
- vitamin c
- piperacillin
- pirfenidone
- +33 more
Phase 3 trials (34)
- melatonin
- sodium nitrite
- methylprednisolone
- desmopressin
- atrial natriuretic peptide
- darbepoetin alfa
- beta erythropoietin
- calcium citrate
- ibuprofen
- dextran
- erythropoetin beta
- ethanol
- deferiprone
- iohexol
- irbesartan
- levocarnitine
- nesiritide
- phentolamine mesylate
- acetaminophen
- pentoxifylline
- spironolactone
- nicotinamide
- curcumin
- mesna
- tranexamic acid
- hydrochlorothiazide
- oxygen
- blood plasma
- l-alanyl-l-glutamine
- colistin
- +4 more
Phase 2 trials (56)
- mannitol
- metformin
- sodium nitrate
- azacitidine
- modimelanotide
- vitamin e
- angiotensin ii
- theophylline
- asfotase alfa
- epoetin
- ambrisentan
- conestat alfa
- deferoxamine
- droxidopa
- gabapentin
- fluorouracil
- hemin
- insulin human
- iron dextran
- iron sucrose
- pembrolizumab
- mb-102
- anidulafungin
- methylene blue
- pterostilbene
- qpi-1002
- sbi-101
- suramin
- thr-184
- urodilatin
- +26 more
Phase 1 trials (19)
Other trials (43)
- nitroglycerin
- Bismuth Subcitrate Potassium
- paroxetine
- chromium ethylenediaminetetraacetic acid
- citalopram
- doxycycline
- duloxetine
- ferric saccharose
- fluvoxamine
- escitalopram
- sertraline
- glycopyrronium
- daptomycin
- iodohippurate
- fluoxetine
- miltefosine
- motexafin gadolinium
- potassium citrate
- lidocaine
- epinephrine
- rocuronium
- desvenlafaxine
- dapsone
- ulinastatin
- glucose
- Anti-thymocyte Globulin (Rabbit)
- xuebijing
- xylitol
- ramipril
- carvedilol
- +13 more
Organizations
Organization Involved with Phase 4 Indications (63)
- Grifols
- German Research Foundation
- Azienda USL 4 Prato
- University of Roma La Sapienza
- Huazhong University of Science and Technology
- Ain Shams University
- Brown University
- Centro Cardiopatici Toscani
- Changhai Hospital
- Fraser Health
- Italian Society of Nephrology
- Mahidol University
- Memorial University of Newfoundland
- Menoufia University
- Onze Lieve Vrouw Hospital
- Shengjing Hospital
- Tokyo Medical and Dental University
- Thomas Jefferson University
- University of Guadalajara
- University of Kentucky
- University of Maryland
- University of Michigan
- University of Oslo
- University of Ottawa
- University of Tampere
- University of Bern
- West Virginia University
- Yonsei University
- University of Leipzig
- Mayo Clinic
- +33 more
Organization Involved with Phase 3 Indications (84)
- Fresenius
- AM-Pharma
- Baxalta
- CorMedix
- Dialysis Clinic, Inc.
- LG
- Swiss National Science Foundation
- Wu Jieping Medical Foundation
- Bambino Gesù Hospital and Research Institute
- Centre Hospitalier Universitaire de Nīmes
- Chang Gung University
- Chulalongkorn University
- Harvard University
- Emory University
- D'Annunzio University of Chieti–Pescara
- Gachon University
- Hospital do Coracao
- Hospital Moinhos de Vento
- Hospital Sirio-Libanes
- Instituto Nacional de Cardiologia Ignacio Chavez
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- McGill University
- Medical College of Wisconsin
- Medical University of Gdansk
- Ilsan Hospital
- Ohio State University
- Seoul National University
- Stanford University
- Taoyuan General Hospital
- Thammasat University
- +54 more
Organization Involved with Phase 2 Indications (59)
- PPD
- Abbott
- AbbVie
- Scios
- Astellas
- Novartis
- AlloCure Inc.
- Angion Biomedica Corp
- Atox Bio Ltd
- MediBeacon
- Abliva
- Sentien Biotechnologies, Inc.
- Thrasos Innovation, Inc.
- Quark Pharmaceuticals
- Medical Research Council
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Region Skane
- Brigham and Women's Hospital
- Bnai Zion Medical Center
- University of London
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Federal University of Health Science of Porto Alegre
- Lund University
- Medical University Innsbruck
- NHS Lothian
- Northern Health and Social Care Trust
- Northwell Health
- Radboud University
- Rocky Mountain Cancer Centers
- Russian Academy of Medical Sciences
- +29 more
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (27)
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Ziekenhuis Oost-Limburg
- Ajou University
- Baylor University
- Benha University
- I.M. Sechenov First Moscow State Medical University
- Instituto Mexicano del Seguro Social
- Nanjing Medical University
- Saint-Joseph University
- Tufts University
- University of Virginia
- Institute of Liver and Biliary Sciences, India
- Satellite Healthcare
- St. Louis University
- University of Chicago
- Tsinghua University
- Icahn School of Medicine at Mount Sinai
- Instituto Nacional de la Nutrición Salvador Zubiran
- University of Montpellier
- Hebrew University
- University of Split
- George Washington University
- New Jeddah Clinic Hospital
- Triax
- Alberta Heritage Foundation for Medical Research
- European Society of Intensive Care Medicine
- Chinese Academy of Medical Sciences